Seattle Genetics has completed the purchase of biopharmaceutical firm Cascadian Therapeutics for $614m, under a definitive merger agreement signed by the companies in January this year.

The merger is part of Seattle Genetics’ strategy to become a global, multi-product oncology company and is expected to boost its late-stage cancer drug pipeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The most advanced program in Cascadian Therapeutics’ pipeline is an investigational oral tyrosine kinase inhibitor (TKI) called tucatinib, which is selective for HER2 growth factor receptor overexpressed in various types of cancer.

Currently, tucatinib is in a randomised global trial involving subjects suffering from HER2-positive (HER2+) metastatic breast cancer, including those with or without brain metastases.

“Tucatinib, which is in an ongoing pivotal trial called HER2CLIMB, has the potential to provide a differentiated approach to treating HER2-positive metastatic breast cancer based on its activity and tolerability profile.”

Patient recruitment for this trial is scheduled to be completed next year.

Seattle Genetics president and CEO Clay Siegall said: “Tucatinib, which is in an ongoing pivotal trial called HER2CLIMB, has the potential to provide a differentiated approach to treating HER2-positive metastatic breast cancer based on its activity and tolerability profile.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“In addition, it may have a role in earlier lines of metastatic breast cancer therapy and in other solid tumours. We look forward to joining efforts with the Cascadian team towards our common goal of improving outcomes for people with cancer.”

Tucatinib has been assessed as a monotherapy and a combination therapy with chemotherapy and other HER2-directed agents such as Herceptin (trastuzumab) and Kadcyla (trastuzumab emtansine).

According to data from Phase Ib clinical trials, the combination of tucatinib, capecitabine and trastuzumab demonstrated a favourable tolerability and efficacy profile in patients with and without brain metastases.